Actinium announces enrollment of first patient in the iomab-act commercial car-t trial at the university of texas southwestern medical center

-       initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial car-t therapy -       iomab-act supported by results of nih funded trial with msk showing effective lymphodepletion of targeted immune cells resulting in negligible rates of car-t toxicities icans and crs and car t-cell persistence with a novel cd19 car-t therapy -       iomab-act has the potential to increase the addressable market for car-t therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents new york , may 6, 2025 /prnewswire/ -- actinium pharmaceuticals, inc. (nyse american: atnm) (actinium or the company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying iomab-act targeted conditioning with a commercial car-t therapy at the university of texas southwestern medical center (utsw) (nct06768905). initial clinical data from this trial is expected in the second half of 2025.
ACT Ratings Summary
ACT Quant Ranking